Streetbeat News

Products Services

ADAG

Adagene presented new clinical data at the ESMO Congress for its ADG126 and Keytruda combination, showing improved response rates and survival in certain cancer patients. The combination maintained a favorable safety profile.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:17 am

AAPL

Apple is facing lower than expected demand for its iPhone 16 Pro and Pro Max models during the first weekend of pre-orders, according to analyst Ming-Chi Kuo. Despite robust overall sales, the Pro models are underperforming, potentially impacting Apple's revenue projections. The iPhone 16 series, introduced with new AI capabilities, is also facing competition in China, and Apple has increased battery replacement prices for the Pro models.

Portfolio Pulse from Rounak Jain

September 16, 2024 | 9:15 am

BCS

HPE

Hewlett Packard Enterprise (HPE) has announced a new private cloud services deal with Barclays, extending their partnership. HPE GreenLake Cloud will be a core component of Barclays' hybrid cloud strategy, aiming to double workload migration over the next three years.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:09 am

NOK

CoreWeave has chosen Nokia to implement its IP routing and optical transport solutions globally, starting with data centers in the US and Europe.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:07 am

STRO

Sutro Biopharma presented updated data from its Phase 1b study of Luvelta in combination with Bevacizumab at ESMO 2024. The combination showed a 56% objective response rate in late-stage ovarian cancer patients, with no new safety signals. The recommended phase 2 dose has been selected, and further expansion is ongoing.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:53 am

BCYC

Bicycle Therapeutics reported promising Phase 1/2 results for its cancer treatments: zelenectide pevedotin, BT5528, and BT7480. Zelenectide pevedotin showed a 45% ORR in metastatic urothelial cancer, while BT5528 and BT7480 demonstrated favorable safety profiles and antitumor activity in advanced solid tumors.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:51 am

NUVB

Nuvation Bio announced promising pooled data from TRUST-I and TRUST-II studies for taletrectinib, showing significant tumor shrinkage in advanced ROS1-positive NSCLC patients. The drug demonstrated durable responses, prolonged progression-free survival, and a favorable safety profile. Nuvation Bio plans to submit a New Drug Application to the FDA in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:51 am

GSK

ITOS

iTeos Therapeutics announced promising interim data from the GALAXIES Lung-201 Phase 2 study, sponsored by GSK, for the belrestotug and dostarlimab combination in treating high PD-L1 non-small cell lung cancer. The combination showed a high objective response rate and a favorable safety profile.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:47 am

ACRV

Acrivon Therapeutics reported promising Phase 2 data for ACR-368 in endometrial cancer, showing a 62.5% response rate in selected patients. The company is advancing ACR-2316 ahead of schedule and making progress with its AP3 Interactome. A webcast with Dr. Ramez N. Eskander is scheduled.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:46 am

IOBT

MRK

IO Biotech announced positive Phase 2 trial results for its cancer vaccine candidate IO102-IO103 in combination with Merck's Keytruda, meeting primary and secondary endpoints without new safety concerns.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:42 am